Tusamitamab Ravtansine

Summary

Tusamitamab Ravtansine (CHEMBL4298098) is a phase-3 clinical-stage antibody drug conjugate; indicated across 2 conditions including non-small cell lung carcinoma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody drug conjugate
• Indications: 2 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298098
Name	Tusamitamab Ravtansine
Type	Antibody drug conjugate
Max phase	3

Also known as: Maytansin-loaded anti-ceacam5 mab, Sar 408701, Sar-408701, SAR-408701, Sar408701, SAR408701, Tusamitamab ravtansine, TUSAMITAMAB RAVTANSINE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
neoplasm	1	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	6
PHASE1	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04154956	PHASE3	TERMINATED	SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
NCT04394624	PHASE2	TERMINATED	Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)
NCT04659603	PHASE2	TERMINATED	Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
NCT05071053	PHASE2	TERMINATED	Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
NCT05245071	PHASE2	TERMINATED	Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
NCT05703555	PHASE2	WITHDRAWN	INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701
NCT05849246	PHASE2	TERMINATED	The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
NCT02187848	PHASE1	TERMINATED	Evaluation of SAR408701 in Patients With Advanced Solid Tumors
NCT03324113	PHASE1	COMPLETED	Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
NCT05429762	PHASE1	TERMINATED	Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).